कंपनी का अवलोकन
Fortress Biotech, Inc. is a biopharmaceutical entity dedicated to the development and commercialization of specialized biopharmaceutical products for specific medical conditions. The company operates within the healthcare sector, specifically in the biotechnology industry, which focuses on creating innovative therapies and treatments to address unmet medical needs. Fortress Biotech, Inc. currently holds a market capitalization of $73.97M and generates an annual revenue of $63.26M, with an employee count listed as N/A in available records. These valuation and revenue figures indicate that the company functions as a mid-sized entity within the biotechnology landscape, possessing a tangible revenue base that supports its research and development activities despite its relatively modest market cap compared to large-cap pharmaceutical peers.
वित्तीय स्वास्थ्य
The company reported a total revenue of $63.26M over the trailing twelve months, yet recorded a net income of -$1,882,000, revealing a significant cost structure where expenses substantially exceeded operating profits before interest and taxes. The EBITDA for the period stood at -$65,560,000, highlighting that the company is currently burning cash to fund its operations and development pipeline. Free cash flow is reported at -$47,286,376, which indicates that the company is not generating positive cash flow from its operations after capital expenditures, thereby limiting its immediate financial flexibility without external financing. The gross margin stands at 48.1%, suggesting that the company retains a healthy portion of revenue after direct production costs, though the operating margin of -29.8% and profit margin of 10.8% present a complex picture where operational inefficiencies or heavy R&D spending are impacting overall profitability. In terms of liquidity, the company holds $79.38M in cash against $67.22M in debt, resulting in a debt-to-equity ratio of 108.09, which suggests a leveraged balance sheet where debt obligations are significant relative to shareholder equity. However, the current ratio of 2.49 indicates that Fortress Biotech, Inc. maintains a conservative short-term liquidity position, holding sufficient current assets to cover its short-term liabilities more than twice over. Furthermore, the return on equity is -108.7% and the return on assets is -26.6%, metrics that reveal that management is currently generating negative returns on the capital invested by shareholders and in the company's assets, reflecting the typical losses incurred during the growth and development phases of a biotechnology firm.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio and forward P/E ratio are both listed as N/A due to the company's lack of positive earnings, meaning these traditional metrics cannot be used to gauge the earnings trajectory or investor expectations for immediate profitability. Investors must therefore rely on alternative valuation measures, specifically the price-to-book ratio of 7.65, which indicates that the market is valuing the company at a significant premium over its book value, likely anticipating future commercial successes or intangible assets not fully captured on the balance sheet. The price-to-sales ratio is 1.17, while the EV/EBITDA stands at -6.77, suggesting that the valuation is currently driven by revenue multiples and asset expectations rather than earnings power. The stock has traded between a 52-week high of $14.64 and a 52-week low of $4.72, and without the current share price explicitly listed in the facts, the precise percentage distance from the high or low cannot be calculated, but the wide trading range of $9.92 reflects high investor sentiment volatility. Additionally, the beta value of 1.45 signifies that the stock is expected to be 45% more volatile than the broader market, indicating that price movements in Fortress Biotech, Inc. will likely amplify market swings.
Growth & Income
Fortress Biotech, Inc. demonstrated a revenue growth of 6.3% year-over-year, whereas the earnings growth year-over-year is N/A due to negative net income, implying that while top-line sales are expanding, the bottom-line profitability has not yet achieved a positive growth trajectory. As the company does not pay dividends, with a dividend yield and payout ratio both listed as N/A, it follows a growth-oriented strategy where earnings are theoretically reinvested into research, development, and commercialization efforts rather than distributed to shareholders. The absence of a dividend yield confirms that the company prioritizes funding its pipeline and operational expansion over providing regular income to investors. Overall, the growth and income profile of Fortress Biotech, Inc. is characterized by positive revenue expansion coupled with negative earnings and a lack of dividend distribution, typical for a biopharmaceutical company in a development or early commercialization stage seeking to build a sustainable market position.